Sevion is a biopharmaceutical company which discovers, develops and acquires innovative products for the treatment of cancer and immunological diseases. The Company applies multiple breakthroughs in drug discovery technology to create new therapeutic product classes, then utilizes development know-how to advance a pipeline of proprietary and partnered product candidates. The Company’s proprietary antibody pipeline includes antibodies against ion channels and GPCRs.
We make every effort to keep our shareholders fully informed about all financial matters in a timely manner. If there is information beyond what is provided on these pages, we welcome all inquiries directly to Sevion or to our investor relations firm. Contact us.
Downloadable Corporate Documents
Certificate of Incorporation
Certificate of Incorporation Amended
Compensation Committee Charter
Code of Business Conduct and Ethics
Audit Committee Charter
Nominating and Corporate Governance Committee Charter
Corporate Governance Guidelines
Certain information contained in or directly accessible from this website includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. The Company’s actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and joint ventures; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this website should be viewed in conjunction with the Company’s periodic filings with the SEC. The Company disclaims any intention or obligation to update or revise any forward-looking statements as a result of developments occurring after the date such statement was first made.